Glycated hemoglobin (HbA1c) is the gold standard for assessing long-term glucose control in diabetes. Ability to predict long-term HbA1c using glucose response from clinical trials of shorter duration is much desired, but uncertainty exists in using short-term glucose biomarker changes to predict long-term HbA1c changes in Type 2 diabetes (T2D) trials. Three common semi-mechanistic PK/PD […]
